Case Series Drug Analysis Print Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 31-Jul-2021 19:00:04 Data Lock Date: Earliest Reaction Date: 05-May-2006 MedDRA Version: MedDRA 24.0 GARDASIL - Product All UK Spontaneous ADR reports for Gardasil until

Analysis Print:

31/07/2021

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--------------------------------|-------|-------|
| Blood disorders | | |
| Anaemia deficiencies | | |
| Iron deficiency anaemia | 1 | 0 |
| Pernicious anaemia | 1 | 0 |
| Anaemias NEC | | |
| Anaemia | 4 | 0 |
| Bleeding tendencies | | |
| Increased tendency to bruise | 2 | 0 |
| Coagulopathies | | |
| Coagulopathy | 1 | 0 |
| Haematological disorders | | |
| Blood disorder | 1 | 0 |
| Lymphatic system disorders NEC | | |
| Lymph node pain | 1 | 0 |
| Lymphadenopathy | 22 | 0 |
| Neutropenias | | |
| Autoimmune neutropenia | 2 | 0 |
| Neutropenia | 2 | 0 |
| Spleen disorders | | |
| Splenomegaly | 1 | 0 |
| Thrombocytopenias | | |
| Immune thrombocytopenia | 5 | 0 |
| Blood disorders SOC TOTAL | 43 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Cardiac disorders | | |
| Cardiac disorders NEC | | |
| Cardiac disorder | 1 | 0 |
| Cardiac signs and symptoms NEC | | |
| Palpitations | 23 | 0 |
| Ischaemic coronary artery disorders | | |
| Angina pectoris | 1 | 0 |
| Rate and rhythm disorders NEC | | |
| Arrhythmia | 1 | 0 |
| Postural orthostatic tachycardia syndrome | 33 | 0 |
| Tachycardia | 11 | 0 |
| Supraventricular arrhythmias | | |
| Sinus arrhythmia | 1 | 0 |
| Sinus tachycardia | 1 | 0 |
| Ventricular arrhythmias and cardiac arrest | | |
| Cardiac arrest | 2 | 1 |
| Pulseless electrical activity | 1 | 0 |
| Cardiac disorders SOC TOTAL | 75 | 1 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| ,,,,,, | | |
|--|-------|-------|
| Reaction Name | Total | Fatal |
| Congenital disorders | | |
| Connective tissue disorders congenital | | |
| Ehlers-Danlos syndrome | 4 | 0 |
| Inborn errors of bilirubin metabolism | | |
| Gilbert's syndrome | 1 | 0 |
| Congenital disorders SOC TOTAL | 5 | 0 |
| | | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|------------------------------|-------|-------|
| Ear disorders | | |
| Ear disorders NEC | | |
| Ear pain | 6 | 0 |
| Hearing disorders NEC | | |
| Auditory disorder | 1 | 0 |
| Hearing losses | | |
| Deafness | 5 | 0 |
| Deafness transitory | 1 | 0 |
| Hypoacusis | 6 | 0 |
| Hyperacusia | | |
| Hyperacusis | 9 | 0 |
| Inner ear signs and symptoms | | |
| Motion sickness | 1 | 0 |
| Tinnitus | 5 | 0 |
| Vertigo | 4 | 0 |
| Ear disorders SOC TOTAL | 38 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Endocrine disorders | | |
| Acute and chronic thyroiditis | | |
| Autoimmune thyroiditis | 2 | 0 |
| Endocrine abnormalities of gonadal function NEC | | |
| Oestrogen deficiency | 1 | 0 |
| Hypothalamic and pituitary disorders NEC | | |
| Lymphocytic hypophysitis | 1 | 0 |
| Thyroid disorders NEC | | |
| Autoimmune thyroid disorder | 1 | 0 |
| Goitre | 1 | 0 |
| Thyroid hypofunction disorders | | |
| Autoimmune hypothyroidism | 1 | 0 |
| Hypothyroidism | 4 | 0 |
| Endocrine disorders SOC TOTAL | 11 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Earliest Reaction Date: 05-May-2006 MedDRA Version: MedDRA 24.0 Reaction Name | Total | Fatal |
|---|-------|-------|
| Eye disorders | | |
| Choroid and vitreous structural change, deposit and degeneration | | |
| Vitreous floaters | 2 | 0 |
| Eyelid movement disorders | | |
| Blepharospasm | 1 | 0 |
| Eyelid ptosis | 3 | 0 |
| Glaucomas (excl congenital) | | |
| Glaucoma | 1 | 0 |
| Iris and ciliary body structural change, deposit and degeneration | | |
| Iris adhesions | 1 | 0 |
| Iris and uveal tract infections, irritations and inflammations | | |
| Iritis | 1 | 0 |
| Lacrimation disorders | | |
| Lacrimation increased | 2 | 0 |
| Lid, lash and lacrimal infections, irritations and inflammations | | |
| Eyelid rash | 1 | 0 |
| Swelling of eyelid | 7 | 0 |
| Ocular disorders NEC | | |
| Dark circles under eyes | 1 | 0 |
| Eye pain | 7 | 0 |
| Eye swelling | 5 | 0 |
| Periorbital pain | 1 | 0 |
| Periorbital swelling | 1 | 0 |
| Ocular infections, inflammations and associated manifestations | | |
| Eye irritation | 1 | 0 |
| Eye pruritus | 3 | 0 |
| Ocular hyperaemia | 3 | 0 |
| Ocular nerve and muscle disorders | | |
| Extraocular muscle paresis | 1 | 0 |
| Eye movement disorder | 18 | 0 |
| Ophthalmoplegia | 1 | 0 |
| Strabismus | 1 | 0 |
| Ocular sensation disorders | | |
| Abnormal sensation in eye | 1 | 0 |
| Asthenopia | 1 | 0 |
| Photophobia | 20 | 0 |
| Pupil disorders | | |
| Miosis | 1 | 0 |
| Mydriasis | 4 | 0 |
| Pupillary disorder | 1 | 0 |
| Visual disorders NEC | | |
| Diplopia | 7 | 0 |
| Halo vision | 1 | 0 |
| Photopsia | 3 | 0 |
| Vision blurred | 59 | 0 |
| Visual field disorders | | |
| Visual field defect | 1 | 0 |
| Visual impairment and blindness (excl colour blindness) | | |
| Blindness | 3 | 0 |
| Blindness transient | 9 | 0 |
| Visual acuity reduced | 1 | 0 |
| Visual impairment | 29 | 0 |
| Eve disorders SOC TOTAL | 203 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Earliest Reaction Date: 05-May-2006 Reaction Name | Total | Fatal |
|---|--------------------|------------|
| Gastrointestinal disorders | | |
| Acute and chronic pancreatitis | | |
| Pancreatitis | 1 | 1 C |
| Anal and rectal disorders NEC | | |
| Anal fissure | 1 | 1 C |
| Colitis (excl infective) | | |
| Colitis | 1 | 1 C |
| Colitis ulcerative | 1 | |
| Crohn's disease | 1 | 1 C |
| Diarrhoea (excl infective) | | |
| Diarrhoea | 33 | 3 C |
| Diarrhoea haemorrhagic | 1 | |
| Dyspeptic signs and symptoms | | |
| Dyspepsia | 5 | 5 0 |
| Flatulence, bloating and distension | | |
| Abdominal distension | Ş | |
| Flatulence | | <u>2</u> C |
| Gastric and oesophageal haemorrhages | | |
| Oesophageal haemorrhage | 1 | |
| Gastritis (excl infective) | | |
| Gastritis | | 2 C |
| Reflux gastritis | | |
| Gastrointestinal and abdominal pains (excl | oral and throat) | |
| Abdominal pain | ý 60 | |
| Abdominal pain lower | ç | |
| Abdominal pain upper | 49 | e c |
| Abdominal rigidity | 1 | |
| Abdominal tenderness | | 2 0 |
| Gastrointestinal atonic and hypomotility dis | orders NEC | |
| Constipation | Ş | e c |
| Gastrointestinal hypomotility | | |
| Gastrooesophageal reflux disease | Ę | 5 0 |
| Gastrointestinal disorders NEC | | |
| Gastric disorder | 2 | 4 C |
| Gastrointestinal disorder | 4 | 4 C |
| Gastrointestinal dyskinetic disorders | | |
| Bowel movement irregularity | | |
| Gastrointestinal motility disorder | | |
| Gastrointestinal inflammatory disorders NE | c | |
| Gastrointestinal inflammation | | 2 0 |
| Gastrointestinal mucosal dystrophies and s | ecretion disorders | |
| Oesophageal mucosal hyperplasia | | |
| Gastrointestinal signs and symptoms NEC | | |
| Abdominal discomfort | 14 | 4 C |
| Dysphagia | ç | |
| Gastrointestinal spastic and hypermotility d | isorders | |
| Frequent bowel movements | | |
| Irritable bowel syndrome | ç | |
| Gingival disorders, signs and symptoms NE | EC | |
| Gingival ulceration | | |
| Gingival haemorrhages | | |
| Gingival bleeding | | |
| Haemorrhoids and gastrointestinal varices | | |
| Haemorrhoids | 1 | 1 C |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Gastrointestinal disorders ointestinal disorders con | t'd | |
| Inguinal hernias | | |
| Inguinal hernia | 2 | 2 0 |
| Intestinal haemorrhages | | |
| Rectal haemorrhage | 1 | 0 |
| Malabsorption syndromes | | |
| Bile acid malabsorption | 1 | 0 |
| Coeliac disease | 7 | ′ 0 |
| Malabsorption | 1 | 0 |
| Nausea and vomiting symptoms | | |
| Cyclic vomiting syndrome | 1 | 0 |
| Nausea | 430 | 0 0 |
| Retching | 4 | 4 O |
| Vomiting | 180 | 0 0 |
| Vomiting projectile | 1 | 0 |
| Non-site specific gastrointestinal haemorrhage | es | |
| Haematemesis | 2 | 2 0 |
| Haematochezia | 1 | 0 |
| Oral dryness and saliva altered | | |
| Dry mouth | 1 | 0 |
| Lip dry | 1 | 0 |
| Oral soft tissue disorders NEC | | |
| Chapped lips | 1 | 0 |
| Lip blister | 1 | 0 |
| Uvulitis | 1 | 0 |
| Oral soft tissue signs and symptoms | | |
| Lip erythema | 1 | 0 |
| Oral discomfort | 1 | 0 |
| Oral mucosal eruption | 1 | 0 |
| Oral pain | 1 | 0 |
| Paraesthesia oral | 13 | s 0 |
| Oral soft tissue swelling and oedema | | |
| Lip swelling | 11 | 0 |
| Peritoneal and retroperitoneal disorders | | |
| Intra-abdominal fluid collection | 1 | 0 |
| Stomatitis and ulceration | | |
| Lip ulceration | 1 | 0 |
| Mouth ulceration | 5 | |
| Tongue disorders | | |
| Tongue ulceration | 1 | 0 |
| Tongue signs and symptoms | | |
| Swollen tongue | 4 | |
| Tongue coated | 1 | |
| Gastrointestinal disorders SOC TOTAL | 922 | - |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Date: 05-May-2006 | Total | Fatal |
|---------------------------------------|---------------------------------------|-------|
| General disorders | | |
| Administration site reactions NEC | | |
| Administration site swelling | · · · · · · · · · · · · · · · · · · · | 1 (|
| Asthenic conditions | | |
| Asthenia | 6 | 7 (|
| Chronic fatigue syndrome | 3 | 1 (|
| Fatigue | 21 | 7 (|
| Malaise | 223 | 3 (|
| Body temperature altered | | |
| Temperature regulation disorder | | 7 (|
| Death and sudden death | | |
| Death | | 1 |
| Febrile disorders | | |
| Pyrexia | 15 | 1 (|
| Feelings and sensations NEC | | |
| Chills | 30 | |
| Feeling abnormal | 38 | 3 (|
| Feeling cold | 19 | 9 |
| Feeling drunk | · · · · · · · · · · · · · · · · · · · | 1 (|
| Feeling hot | 59 | 9 |
| Feeling jittery | | 2 |
| Feeling of body temperature change | | 4 |
| Sensation of foreign body | · · · · · · · · · · · · · · · · · · · | 1 (|
| Temperature intolerance | | 6 |
| Thirst | | 3 |
| Gait disturbances | | |
| Gait disturbance | 1: | 2 |
| Gait inability | 1 | 1 (|
| Loss of control of legs | | 3 (|
| General signs and symptoms NEC | | |
| Condition aggravated | | 6 |
| Crying | | 5 |
| Exercise tolerance decreased | | 5 |
| Foaming at mouth | | 2 |
| General physical health deterioration | · · · · · · · · · · · · · · · · · · · | 1 (|
| Glassy eyes | · · · · · · · · · · · · · · · · · · · | 1 (|
| III-defined disorder | | 4 |
| Illness | 2 | 5 |
| Induration | · · · · · · · · · · · · · · · · · · · | 1 |
| Influenza like illness | 1 | 9 |
| Local reaction | | 5 |
| Peripheral swelling | 98 | 3 |
| Screaming | · · · · · · · · · · · · · · · · · · · | 1 |
| Secretion discharge | · · · · · · · · · · · · · · · · · · · | 1 |
| Swelling | 14 | |
| Swelling face | 20 | D |
| Healing abnormal NEC | | |
| Impaired healing | | 2 |
| Hernias NEC | | |
| Hernia | | 1 |
| Inflammations | | |
| Inflammation | | 6 |
| Serositis | | 1 |
| Injection site reactions | | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Earliest Reaction Date: 05-May-2006 | MedDRA Version: MedDRA 24.0 | Eatol |
|--|-----------------------------|--------------|
| Reaction Name General disorders General disorders cont'd | Total | <u>Fatal</u> |
| | | |
| Injected limb mobility decreased | | 2 0 |
| Injection site bruising | | 4 (|
| Injection site discomfort | | |
| Injection site erythema | 1 | |
| Injection site haemorrhage | | 2 (|
| Injection site hypoaesthesia | | 5 (|
| Injection site induration | | 2 (|
| Injection site inflammation | | |
| Injection site joint pain | | |
| Injection site mass | 1. | |
| Injection site movement impairment | | |
| Injection site nerve damage | | |
| Injection site oedema | | |
| Injection site pain | 2 | |
| Injection site paraesthesia | | 1 C |
| Injection site pruritus | | 8 (|
| Injection site rash | | 1 (|
| Injection site reaction | | |
| Injection site swelling | 2 | |
| Injection site warmth | | 2 (|
| Mass conditions NEC | | |
| Mass | | 2 0 |
| Mucosal findings abnormal | | |
| Mucosal ulceration | | 1 C |
| Oedema NEC | | |
| Face oedema | | 1 C |
| Localised oedema | | 1 (|
| Oedema peripheral | | 5 C |
| Pain and discomfort NEC | | |
| Axillary pain | | 2 0 |
| Chest discomfort | 2 | |
| Chest pain | 3 | |
| Discomfort | 1 | 1 (|
| Facial pain | | 1 (|
| Non-cardiac chest pain | | 2 (|
| Pain | 6 | 9 (|
| Tenderness | | 3 (|
| Therapeutic and nontherapeutic responses | | |
| Adverse drug reaction | 1: | 5 (|
| Adverse event | | 1 (|
| Adverse reaction | | 2 (|
| Drug ineffective | | 2 (|
| Drug resistance | | 1 (|
| Immediate post-injection reaction | | 1 (|
| Therapeutic response unexpected | | 1 (|
| Vaccination failure | | 1 (|
| Trophic disorders | | |
| Atrophy | | 1 (|
| Hyperplasia | | 1 (|
| Vaccination site reactions | | |
| Extensive swelling of vaccinated limb | | 1 (|
| Vaccination site bruising | | 1 (|
| Vaccination site discomfort | | 1 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Earliest Reaction Date. 05-May-2006 MedDRA Version. MedDRA | 124.0 | |
|--|----------|-------|
| Reaction Name | <u> </u> | Fatal |
| General disorders General disorders cont'd | | |
| Vaccination site erythema | 10 | 0 |
| Vaccination site inflammation | 2 | 0 |
| Vaccination site irritation | 1 | 0 |
| Vaccination site joint movement impairment | 1 | 0 |
| Vaccination site joint pain | 1 | 0 |
| Vaccination site mass | 2 | 0 |
| Vaccination site movement impairment | 2 | 0 |
| Vaccination site nerve damage | 1 | 0 |
| Vaccination site pain | 13 | 0 |
| Vaccination site paraesthesia | 1 | 0 |
| Vaccination site pruritus | 4 | 0 |
| Vaccination site rash | 3 | 0 |
| Vaccination site swelling | 11 | 0 |
| Vaccination site warmth | 2 | 0 |
| General disorders SOC TOTAL | 1449 | 1 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Hepatic disorders | | |
| Cholestasis and jaundice | | |
| Jaundice | 2 | 0 |
| Hepatic and hepatobiliary disorders NEC | | |
| Liver disorder | 1 | 0 |
| Hepatic enzymes and function abnormalities | | |
| Hepatic function abnormal | 1 | 0 |
| Hepatobiliary signs and symptoms | | |
| Hepatic pain | 1 | 0 |
| Hepatocellular damage and hepatitis NEC | | |
| Autoimmune hepatitis | 1 | 0 |
| Hepatitis | 1 | 0 |
| Hepatitis acute | 1 | 0 |
| Hepatic disorders SOC TOTAL | 8 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Immune system disorders | | |
| Allergic conditions NEC | | |
| Allergic oedema | 1 | 0 |
| Hypersensitivity | 33 | 0 |
| Multiple allergies | 2 | 0 |
| Allergies to foods, food additives, drugs and other chemicals | | |
| Drug hypersensitivity | 1 | 0 |
| Food allergy | 2 | 0 |
| Reaction to excipient | 2 | 0 |
| Rubber sensitivity | 1 | 0 |
| Anaphylactic and anaphylactoid responses | | |
| Anaphylactic reaction | 32 | 0 |
| Anaphylactic shock | 2 | 0 |
| Autoimmune disorders NEC | | |
| Autoimmune disorder | 6 | 0 |
| Immune and associated conditions NEC | | |
| Decreased immune responsiveness | 1 | 0 |
| Immune system disorder | 7 | 0 |
| Immune system disorders SOC TOTAL | 90 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | | otal | Fatal |
|--|--------|------|----------|
| Infections | | | i atai |
| Abdominal and gastrointestinal infections | | | |
| Abdominal abscess | | 1 | 0 |
| Appendicitis | | 1 | 0 |
| Appendicitis perforated | | 1 | 0 |
| Gastroenteritis | | 1 | 0 |
| Gastrointestinal infection | | 1 | 0 |
| Bacterial infections NEC | | - 1 | U |
| Cellulitis | | 1 | 0 |
| | | 1 | 0 |
| Candida infections | | | 0 |
| Candida infection | | 1 | 0 |
| Vulvovaginal candidiasis | | 1 | 0 |
| Central nervous system and spinal infections | 5 | | - |
| Encephalitis | | 4 | 0 |
| Subdural abscess | | 1 | C |
| Coxsackie viral infections | | | |
| Hand-foot-and-mouth disease | | 1 | C |
| Dental and oral soft tissue infections | | | |
| Gingivitis | | 1 | C |
| Ear infections | | | |
| Otitis media | | 1 | 0 |
| Epstein-Barr viral infections | | | |
| Epstein-Barr virus infection | | 1 | C |
| Infectious mononucleosis | | 1 | C |
| Eye and eyelid infections | | | |
| Conjunctivitis | | 2 | C |
| Female reproductive tract infections | | | |
| Amniotic cavity infection | | 1 | C |
| Pelvic inflammatory disease | | 1 | C |
| Vulvovaginitis | | 1 | C |
| Haemophilus infections | | | |
| Haemophilus infection | | 1 | C |
| Herpes viral infections | | | |
| Herpes zoster | | 5 | C |
| Oral herpes | | 1 | C |
| Infections NEC | | | |
| Infection | | 2 | C |
| Infection susceptibility increased | | 1 | C |
| Injection site infection | | 1 | |
| Localised infection | | 1 | |
| Influenza viral infections | | | , |
| Influenza | | 2 | C |
| Lower respiratory tract and lung infections | | 2 | L. |
| Bronchitis | | 1 | C |
| Lower respiratory tract infection | | 2 | |
| | | 2 | Ľ |
| Papilloma viral infections | | 2 | C |
| Papilloma viral infection | | 2 | (|
| Sepsis, bacteraemia, viraemia and fungaem | ia NEC | 4 | <i>(</i> |
| Neutropenic sepsis | | ľ | (|
| Sepsis | | 1 | (|
| Septic rash | | 1 | (|
| Staphylococcal infections | | | |
| Staphylococcal infection | | 1 | (|
| Streptococcal infections | | | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| , | | |
|---|-------|-------|
| Reaction Name | Total | Fatal |
| Infections Infections cont'd | | |
| Beta haemolytic streptococcal infection | 1 | 0 |
| Upper respiratory tract infections | | |
| Nasopharyngitis | 7 | 0 |
| Pharyngitis | 3 | 0 |
| Sinusitis | 2 | 0 |
| Tonsillitis | 3 | 0 |
| Urinary tract infections | | |
| Urinary tract infection | 1 | 0 |
| Viral infections NEC | | |
| Gastroenteritis viral | 2 | 0 |
| Post viral fatigue syndrome | 11 | 0 |
| Viral infection | 4 | 0 |
| Infections SOC TOTAL | 80 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Injuries | | |
| Bone and joint injuries NEC | | |
| Joint injury | 1 | C |
| Exposures associated with pregnancy, delivery and lactation | | |
| Exposure during pregnancy | 4 | C |
| Foetal exposure during pregnancy | 4 | C |
| Fractures and dislocations NEC | | |
| Joint dislocation | 1 | C |
| Medication errors, product use errors and issues NEC | | |
| Circumstance or information capable of leading to medication error | 1 | C |
| Non-site specific injuries NEC | | |
| Fall | 7 | C |
| Injury | 1 | C |
| Wound haemorrhage | 1 | C |
| Overdoses NEC | | |
| Overdose | 1 | C |
| Poisoning and toxicity | | |
| Metal poisoning | 1 | C |
| Poisoning | 1 | C |
| Product administration errors and issues | | |
| Expired product administered | 1 | C |
| Extra dose administered | 2 | C |
| Inappropriate schedule of product administration | 4 | C |
| Product administered at inappropriate site | 3 | C |
| Wrong product administered | 1 | C |
| Site specific injuries NEC | | |
| Head injury | 1 | C |
| Skin injuries NEC | | |
| Contusion | 10 | C |
| Thermal burns | | |
| Thermal burn | 1 | C |
| Vaccination related complications | | |
| Vaccination complication | 8 | C |
| Injuries SOC TOTAL | 54 | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Earliest Reaction Date: 05-May-2006 Reaction Name | MedDRA Version: MedDRA 24.0 | Total | Fatal |
|---|-----------------------------|-------|--------|
| Investigations | | | r atal |
| Blood gas and acid base analyses | | | |
| Oxygen saturation decreased | | 2 | (|
| Carbohydrate tolerance analyses (incl diabe | tes) | 2 | , |
| Blood glucose decreased | | 2 | (|
| Cardiac auscultatory investigations | | 2 | , |
| Cardiac murmur | | 1 | (|
| Heart sounds abnormal | | 1 | (|
| ECG investigations | | 1 | |
| Electrocardiogram QT prolonged | | 1 | (|
| Electrocardiogram T wave inversion | | 1 | (|
| Endocrine analyses and imaging NEC | | | , |
| Hormone level abnormal | | 1 | (|
| Heart rate and pulse investigations | | 1 | , |
| Heart rate abnormal | | 3 | (|
| Heart rate decreased | | 5 | (|
| Heart rate increased | | 17 | (|
| Heart rate irregular | | 6 | (|
| Pulse abnormal | | 3 | (|
| Pulse absent | | 2 | (|
| Pulse pressure decreased | | 2 | (|
| Immunoglobulin analyses | | 1 | Ĺ |
| | | 1 | C |
| Blood immunoglobulin A increased Liver function analyses | | 1 | Ĺ |
| Blood bilirubin increased | | - 1 | (|
| | | 1 | (|
| Hepatic enzyme increased <i>Mineral and electrolyte analyses</i> | | 1 | (|
| Blood iron decreased | | 2 | ſ |
| | | 3 | C |
| Blood magnesium decreased Blood selenium decreased | | | |
| | | | (|
| Blood zinc decreased | | 1 | (|
| Ophthalmic function diagnostic procedures Corneal reflex decreased | | - 1 | (|
| | | 1 | (|
| Physical examination procedures and organ | system status | 4 | (|
| Body temperature abnormal | | | (|
| Body temperature decreased | | | |
| Body temperature fluctuation | | 3 | (|
| Body temperature increased | | 15 | (|
| Respiratory rate increased | | 5 | (|
| Weight decreased | | 3 | (|
| Weight increased | | 1 | (|
| Pituitary analyses anterior | | | |
| Blood growth hormone abnormal | | 1 | (|
| Blood thyroid stimulating hormone abnorm | ai | 1 | (|
| Platelet analyses | | | |
| Platelet count decreased | | 1 | (|
| Protein analyses NEC | | | |
| Blood albumin abnormal | | 1 | (|
| C-reactive protein increased | | 2 | |
| Protein total abnormal | | 1 | (|
| Reproductive hormone analyses | | | |
| Progesterone increased | | 1 | (|
| Reproductive organ and breast histopatholog | gy procedures | | |
| Smear cervix abnormal | | 1 | (|

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Earliest Reaction Date. 05-May-2000 | Meudra Version. Meudra 24.0 | | |
|--|-----------------------------|-------|-------|
| Reaction Name | | Total | Fatal |
| Investigations Investigations cont'd | | | |
| Tissue enzyme analyses NEC | | | |
| Blood lactate dehydrogenase increased | | 1 | 0 |
| Enzyme level increased | | 1 | 0 |
| Toxicology laboratory analyses | | | |
| Blood chromium decreased | | 1 | 0 |
| Urinalysis NEC | | | |
| Blood urine present | | 1 | 0 |
| Vascular tests NEC (incl blood pressure) | | | |
| Blood pressure abnormal | | 1 | 0 |
| Blood pressure decreased | | 6 | 0 |
| Blood pressure immeasurable | | 1 | 0 |
| Blood pressure increased | | 2 | 0 |
| Vitamin analyses | | | |
| Vitamin B12 increased | | 1 | 0 |
| Vitamin D decreased | | 3 | 0 |
| Investigations SOC TOTAL | | 112 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Metabolic disorders | | |
| Appetite disorders | | |
| Appetite disorder | 3 | 0 |
| Decreased appetite | 28 | 0 |
| Salt craving | 2 | 0 |
| Calcium metabolism disorders | | |
| Tetany | 1 | 0 |
| Diabetes mellitus (incl subtypes) | | |
| Type 1 diabetes mellitus | 5 | 0 |
| Diabetic complications NEC | | |
| Diabetic ketoacidosis | 2 | 0 |
| Fat soluble vitamin deficiencies and disorders | | |
| Vitamin D deficiency | 6 | 0 |
| Food malabsorption and intolerance syndromes (excl sugar intolerance) | | |
| Dairy intolerance | 1 | 0 |
| Food intolerance | 2 | 0 |
| Gluten sensitivity | 3 | 0 |
| General nutritional disorders NEC | | |
| Abnormal loss of weight | 10 | 0 |
| Abnormal weight gain | 1 | 0 |
| Feeding disorder | 3 | 0 |
| Weight gain poor | 1 | 0 |
| Hyperglycaemic conditions NEC | | |
| Insulin resistance | 1 | 0 |
| Hypoglycaemic conditions NEC | | |
| Hypoglycaemia | 1 | 0 |
| Metabolic acidoses (excl diabetic acidoses) | | |
| Lactic acidosis | 1 | 0 |
| Metabolic disorders NEC | | |
| Metabolic disorder | 1 | 0 |
| Mineral related disorders NEC | | |
| Mineral deficiency | 1 | 0 |
| Sugar intolerance (excl glucose intolerance) | | |
| Lactose intolerance | 2 | 0 |
| Total fluid volume decreased | | |
| Dehydration | 1 | 0 |
| Vitamin deficiencies NEC | | |
| Multi-vitamin deficiency | 2 | C |
| Water soluble vitamin deficiencies | | |
| Vitamin B12 deficiency | 4 | C |
| Metabolic disorders SOC TOTAL | 82 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | | Total | Fatal |
|--|----------------|-------|-------|
| Muscle & tissue disorders | | | |
| Arthropathies NEC | | | |
| Arthritis | | 1 | 0 |
| Arthropathy | | 3 | 0 |
| Seronegative arthritis | | 1 | 0 |
| Bone related signs and symptoms | | | |
| Bone pain | | 5 | 0 |
| Coccydynia | | 1 | 0 |
| Pain in jaw | | 4 | 0 |
| Spinal pain | | 2 | 0 |
| Cartilage disorders | | | |
| Osteochondrosis | | 1 | 0 |
| Extremity deformities | | | |
| Finger deformity | | 1 | 0 |
| Foot deformity | | 1 | 0 |
| Joint related disorders NEC | | | |
| Hypermobility syndrome | | 1 | 0 |
| Joint lock | | 1 | 0 |
| Periarthritis | | 2 | 0 |
| Joint related signs and symptoms | | | |
| Arthralgia | | 97 | 0 |
| Joint noise | | 2 | 0 |
| Joint range of motion decreased | | 1 | 0 |
| Joint stiffness | | 7 | 0 |
| Joint swelling | | 13 | 0 |
| Ligament disorders | | | |
| Ligament pain | | 1 | 0 |
| Muscle pains | | | |
| Fibromyalgia | | 3 | 0 |
| Myalgia | | 47 | 0 |
| Muscle related signs and symptoms NEC | | | |
| Muscle atrophy | | 1 | 0 |
| Muscle fatigue | | 5 | 0 |
| Muscle spasms | | 27 | 0 |
| Muscle tightness | | 2 | 0 |
| Muscle twitching | | 22 | 0 |
| Muscle tone abnormalities | | | |
| Muscle rigidity | | 18 | 0 |
| Trismus | | 1 | 0 |
| Muscle weakness conditions | | | |
| Muscular weakness | | 56 | 0 |
| Musculoskeletal and connective tissue cond | litions NEC | | |
| Back disorder | | 1 | 0 |
| Growth retardation | | 1 | 0 |
| Mobility decreased | | 5 | 0 |
| Muscle contracture | | 1 | 0 |
| Musculoskeletal stiffness | | 30 | 0 |
| Posture abnormal | | 1 | 0 |
| Weight bearing difficulty | | 4 | 0 |
| Musculoskeletal and connective tissue pain | and discomfort | | |
| Back pain | | 29 | 0 |
| Growing pains | | 1 | C |
| Limb discomfort | | 17 | 0 |
| Musculoskeletal chest pain | | 5 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Editest reddion Bate. 66 May 2000 | | | |
|---|-------|-------|-------|
| Reaction Name | | Total | Fatal |
| Muscle & tissue disordersle & tissue disorders co | ont'd | | |
| Musculoskeletal discomfort | | 2 | 0 |
| Musculoskeletal pain | | 3 | 0 |
| Neck pain | | 30 | 0 |
| Pain in extremity | | 161 | 0 |
| Rheumatoid arthropathies | | | |
| Juvenile idiopathic arthritis | | 1 | 0 |
| Rheumatoid arthritis | | 1 | 0 |
| Soft tissue disorders NEC | | | |
| Axillary mass | | 1 | 0 |
| Groin pain | | 1 | 0 |
| Spondyloarthropathies | | | |
| Arthritis reactive | | 2 | 0 |
| Synovial disorders | | | |
| Synovitis | | 1 | 0 |
| Tendon disorders | | | |
| Tendonitis | | 1 | 0 |
| Muscle & tissue disorders SOC TOTAL | | 626 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Neoplasms | | |
| Bone neoplasms malignant (excl sarcomas) | | |
| Bone cancer | 1 | 0 |
| Cervix neoplasms malignant | | |
| Cervix carcinoma | 1 | 0 |
| Islet cell neoplasms and APUDoma NEC | | |
| Pancreatic neuroendocrine tumour metastatic | 1 | 0 |
| Leukaemias acute lymphocytic | | |
| T-cell type acute leukaemia | 1 | 1 |
| Metastases to specified sites | | |
| Metastases to liver | 1 | 0 |
| Reproductive neoplasms male benign NEC | | |
| Penile wart | 1 | 0 |
| Skin neoplasms benign | | |
| Anogenital warts | 2 | 0 |
| Skin papilloma | 1 | 0 |
| Uterine neoplasms benign | | |
| Uterine leiomyoma | 1 | 0 |
| Neoplasms SOC TOTAL | 10 | 1 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | | Total | Fatal |
|--|--------------------------|-------|-------|
| Nervous system disorders | | | |
| Abnormal reflexes | | 0 | 0 |
| Areflexia | | 2 | 0 |
| Absence seizures | | | • |
| Petit mal epilepsy | | 3 | 0 |
| Autonomic nervous system disorders | | | |
| Autonomic nervous system imbalance | | 2 | 0 |
| Autonomic neuropathy | | 1 | 0 |
| Central nervous system haemorrhages and ce | erebrovascular accidents | | |
| Brain stem stroke | | 1 | 0 |
| Cerebral thrombosis | | 1 | 0 |
| Cerebrovascular accident | | 2 | 0 |
| Lacunar infarction | | 1 | 0 |
| Coordination and balance disturbances | | | - |
| Ataxia | | 4 | 0 |
| Balance disorder | | 8 | 0 |
| Coordination abnormal | | 5 | 0 |
| Dysstasia | | 6 | 0 |
| Nystagmus | | 1 | 0 |
| Cortical dysfunction NEC | | | - |
| Aphasia | | 3 | 0 |
| Dyslexia | | 1 | 0 |
| Dyspraxia | | 1 | 0 |
| Demyelinating disorders NEC | | | |
| Acute disseminated encephalomyelitis | | 1 | 0 |
| Disturbances in consciousness NEC | | | |
| Altered state of consciousness | | 1 | 0 |
| Consciousness fluctuating | | 2 | 0 |
| Depressed level of consciousness | | 6 | 0 |
| Lethargy | | 63 | 0 |
| Loss of consciousness | | 31 | 0 |
| Somnolence | | 46 | 0 |
| Syncope | | 275 | 0 |
| Disturbances in sleep phase rhythm | | | - |
| Irregular sleep wake rhythm disorder | | 2 | 0 |
| Dyskinesias and movement disorders NEC | | | - |
| Dyskinesia | | 35 | 0 |
| Fine motor skill dysfunction | | 1 | 0 |
| Hypokinesia | | 3 | 0 |
| Motor dysfunction | | 4 | 0 |
| Movement disorder | | 7 | 0 |
| Encephalitis NEC | | | |
| Encephalitis autoimmune | | 1 | 0 |
| Noninfective encephalitis | | 1 | 0 |
| Facial cranial nerve disorders | | | |
| Bell's palsy | | 3 | 0 |
| Facial paralysis | | 3 | 0 |
| Generalised tonic-clonic seizures | | | |
| Generalised tonic-clonic seizure | | 8 | C |
| Headaches NEC | | | |
| Cluster headache | | 5 | 0 |
| Headache | | 461 | 0 |
| Tension headache | | 3 | C |
| Increased intracranial pressure disorders | | | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Nervous system disorders us system disorders cont'd | | |
| Idiopathic intracranial hypertension | 1 | 0 |
| Intracranial pressure increased | 1 | 0 |
| Memory loss (excl dementia) | | |
| Amnesia | 11 | 0 |
| Memory impairment | 10 | 0 |
| Mental impairment (excl dementia and memory loss) | | |
| Cognitive disorder | 9 | 0 |
| Disturbance in attention | 22 | 2 0 |
| Mental impairment | 2 | |
| Migraine headaches | | |
| Migraine | 28 | 0 |
| Migraine with aura | 2 | c 0 |
| Mononeuropathies | | |
| Peroneal nerve palsy | 1 | 0 |
| Multiple sclerosis acute and progressive | | |
| Multiple sclerosis | 1 | 0 |
| Muscle tone abnormal | | |
| Hypotonia | 10 | 0 |
| Narcolepsy and hypersomnia | | |
| Cataplexy | 1 | 0 |
| Hypersomnia | 10 | |
| Narcolepsy | 3 | C |
| Nervous system cysts and polyps | | |
| Colloid brain cyst | 1 | 0 |
| Pineal gland cyst | 1 | 0 |
| Nervous system disorders NEC | | |
| Cerebral disorder | 1 | 0 |
| Nervous system disorder | 5 | |
| Neurologic visual problems NEC | | |
| Tunnel vision | 1 | 0 |
| Neurological signs and symptoms NEC | | |
| Dizziness | 688 | C |
| Dizziness exertional | 1 | 0 |
| Dizziness postural | 13 | 1 |
| Head discomfort | 5 | |
| Hyporesponsive to stimuli | 1 | 0 |
| Myoclonus | 1 | |
| Patient elopement | 1 | 0 |
| Presyncope | 21 | 0 |
| Slow response to stimuli | 3 | C |
| Unresponsive to stimuli | 25 | c c |
| Olfactory nerve disorders | | |
| Anosmia | 1 | 0 |
| Paraesthesias and dysaesthesias | | |
| Burning sensation | 7 | d o |
| Hyperaesthesia | 6 | c c |
| Hypoaesthesia | 83 | C |
| Paraesthesia | 99 | |
| Paralysis and paresis (excl cranial nerve) | | |
| Diplegia | 2 | e c |
| Hemiparesis | 6 | |
| Hemiplegia | 1 | |
| Monoplegia | 10 | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Nervous system disorders us system disorders cont'd | | |
| Paralysis | 11 | 0 |
| Paraplegia | 1 | 0 |
| Peripheral paralysis | 1 | 0 |
| Quadriplegia | 1 | 0 |
| Peripheral neuropathies NEC | | |
| Peripheral sensory neuropathy | 1 | 0 |
| Seizures and seizure disorders NEC | | |
| Change in seizure presentation | 1 | 0 |
| Epilepsy | 9 | 0 |
| Febrile convulsion | 1 | 0 |
| Partial seizures | 1 | 0 |
| Psychogenic seizure | 1 | 0 |
| Seizure | 58 | 0 |
| Seizure anoxic | 1 | 0 |
| Seizure like phenomena | 4 | 0 |
| Tonic clonic movements | 5 | 0 |
| Tonic convulsion | 1 | 0 |
| Sensory abnormalities NEC | | |
| Ageusia | 1 | 0 |
| Complex regional pain syndrome | 8 | 0 |
| Dysgeusia | 2 | 0 |
| Neuralgia | 4 | 0 |
| Sensory disturbance | 7 | 0 |
| Sensory loss | 9 | 0 |
| Taste disorder | 2 | 0 |
| Speech and language abnormalities | | |
| Dysarthria | 7 | 0 |
| Incoherent | 1 | 0 |
| Slow speech | 4 | 0 |
| Speech disorder | 4 | 0 |
| Spinal cord and nerve root disorders NEC | | |
| Spinal cord oedema | 1 | 0 |
| Structural brain disorders NEC | | |
| Brain injury | 1 | 0 |
| Tremor (excl congenital) | | |
| Tremor | 64 | 0 |
| Nervous system disorders SOC TOTAL | 2311 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Pregnancy conditions | | |
| Abortions not specified as induced or spontaneous | | |
| Abortion | 1 | 0 |
| Abortions spontaneous | | |
| Abortion spontaneous | 1 | 0 |
| Abortion threatened | 1 | 0 |
| Gestational age and weight conditions | | |
| Premature baby | 1 | 1 |
| Hypertension associated disorders of pregnancy | | |
| Pre-eclampsia | 2 | 0 |
| Labour onset and length abnormalities | | |
| Premature labour | 1 | 0 |
| Maternal complications of pregnancy NEC | | |
| Cervical incompetence | 1 | 0 |
| Pregnancy conditions SOC TOTAL | 8 | 1 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|----------------------------|-------|-------|
| Product label issues | | |
| Product lot number issue | 1 | 0 |
| Product quality issues NEC | | |
| Product origin unknown | 5 | 0 |
| Product substitution issue | 1 | 0 |
| null SOC TOTAL | 7 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Date: 05-May-2006 MedDRA Version | Total | Fatal |
|---|-------|-------|
| Psychiatric disorders | | |
| Abnormal behaviour NEC | | |
| Abnormal behaviour | 7 | c d |
| Staring | 1 | |
| Affect alterations NEC | | |
| Inappropriate affect | 1 | c c |
| Anxiety disorders NEC | | |
| Generalised anxiety disorder | 1 | 0 |
| Anxiety symptoms | | |
| Agitation | 2 | 0 |
| Anxiety | 32 | |
| Nervousness | 2 | |
| Stress | 2 | |
| Behaviour and socialisation disturbances | | |
| Aggression | 2 | |
| Disinhibition | 1 | |
| Paranoia | 2 | C |
| Personality change | 7 | |
| Social avoidant behaviour | 1 | |
| Bipolar disorders | | |
| Bipolar disorder | 1 | C |
| Cognitive and attention disorders and disturbances NEC | | |
| Mental fatigue | 2 | C |
| Confusion and disorientation | _ | |
| Confusional state | 19 | C |
| Disorientation | 14 | |
| Deliria | | |
| Delirium | 2 | C |
| Delusional symptoms | | |
| Delusion | 1 | C |
| Depressive disorders | | |
| Depression | 14 | C |
| Depression suicidal | 4 | |
| Disturbances in initiating and maintaining sleep | | |
| Insomnia | 16 | C |
| Dyssomnias | 10 | |
| Poor quality sleep | 1 | c |
| Eating disorders NEC | | |
| Anorexia nervosa | 1 | C |
| Eating disorder | 1 | |
| Emotional and mood disturbances NEC | | |
| Anger | 2 | |
| Emotional disorder | 3 | |
| Emotional distress | 6 | |
| Mood altered | 2 | |
| Fear symptoms and phobic disorders (incl social phobia) | 2 | |
| Claustrophobia | 1 | |
| Phobia | 1 | |
| Social anxiety disorder | 3 | |
| - | 3 | |
| Fluctuating mood symptoms | | |
| Mood swings | 3 | (|
| Hallucinations (excl sleep-related) | | |
| Hallucination | 3 | |
| Hallucination, auditory | 3 | (|

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name Psychiatric disorders cont'd | Total | Fatal |
|--|-------|-------|
| | 4 | |
| Hallucination, visual | | |
| Increased physical activity levels | | |
| Restlessness | 1 | |
| Mental disorders NEC | | |
| Mental disorder | 4 | |
| Mental status changes | 1 | |
| Mood alterations with depressive symptoms | | |
| Decreased interest | 1 | C |
| Depressed mood | 4 | C |
| Tearfulness | 12 | C |
| Mood disorders NEC | | |
| Apathy | 3 | C |
| Listless | 1 | C |
| Obsessive-compulsive disorders and symptoms | | |
| Obsessive-compulsive disorder | 1 | 0 |
| Panic attacks and disorders | | |
| Panic attack | 5 | |
| Panic reaction | 4 | |
| Parasomnias | | |
| Sleep terror | 1 | 0 |
| Perception disturbances NEC | | |
| Deja vu | 1 | 0 |
| Near death experience | 1 | |
| Personality disorders NEC | | |
| Self esteem decreased | 1 | |
| Personality disorders with anxious behaviour (Cluster C) | | |
| Dependent personality disorder | 1 | |
| | | |
| Pervasive developmental disorders NEC | 1 | |
| Autism spectrum disorder | | |
| Psychiatric symptoms NEC | | |
| Psychiatric symptom | 1 | C |
| Psychotic disorder NEC | | |
| Psychotic disorder | 1 | |
| Sleep disorders NEC | | |
| Sleep disorder | 12 | C |
| Somatic symptom disorders | | |
| Conversion disorder | 4 | 0 |
| Somatic symptom disorder | 1 | C |
| Speech and language usage disturbances | | |
| Logorrhoea | 1 | C |
| Speech articulation and rhythm disturbances | | |
| Dysphemia | 1 | C |
| Suicidal and self-injurious behaviour | | |
| Intentional self-injury | 3 | |
| Suicidal ideation | 4 | |
| Suicide attempt | 1 | |
| Thinking disturbances | | |
| Thought blocking | 1 | 0 |
| Tic disorders | | |
| Tic | 2 | (|
| Psychiatric disorders SOC TOTAL | 240 | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021

Renal & urinary disorders SOC TOTAL

Data Lock Date: 31-Jul-2021 19:00:04 MedDRA Version: MedDRA 24.0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

29

Earliest Reaction Date: 05-May-2006 Fatal Reaction Name Total Renal & urinary disorders Bladder and urethral symptoms Bladder pain 1 Dysuria 1 Incontinence 1 Urinary incontinence 11 2 Urinary retention Bladder disorders NEC Bladder disorder 1 Bladder infections and inflammations Cystitis noninfective 1 Genital and urinary tract disorders NEC Urinary tract disorder 3 Genitourinary tract infections and inflammations NEC Urinary tract inflammation Glomerulonephritis and nephrotic syndrome Nephrotic syndrome Renal disorders NEC Renal disorder Renal vascular and ischaemic conditions Renal vasculitis Urinary abnormalities Proteinuria 2 Urinary tract signs and symptoms NEC Haemorrhage urinary tract 1 Renal pain 1

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--|-------|-------|
| Reproductive & breast disorders | | |
| Breast disorders NEC | | |
| Gynaecomastia | 1 | 0 |
| Nipple disorder | 1 | 0 |
| Breast signs and symptoms | | |
| Breast pain | 1 | 0 |
| Nipple pain | 1 | 0 |
| Cervix disorders NEC | | |
| Cervical dysplasia | 2 | 0 |
| Menopausal effects NEC | | |
| Premature menopause | 2 | 0 |
| Menstruation and uterine bleeding NEC | | |
| Dysmenorrhoea | 6 | 0 |
| Menstrual disorder | 7 | 0 |
| Menstruation irregular | 12 | 0 |
| Premenstrual pain | 1 | 0 |
| Premenstrual syndrome | 1 | 0 |
| Menstruation with decreased bleeding | | Ū |
| Amenorrhoea | 11 | 0 |
| Menstruation delayed | 3 | 0 |
| Oligomenorrhoea | 2 | 0 |
| Menstruation with increased bleeding | _ | Ū |
| Heavy menstrual bleeding | 13 | 0 |
| Polymenorrhoea | 1 | 0 |
| Ovarian and fallopian tube cysts and neoplasms | | - |
| Polycystic ovaries | 2 | 0 |
| Ovarian and fallopian tube disorders NEC | | - |
| Ovarian disorder | 1 | 0 |
| Ovarian failure | 3 | 0 |
| Reproductive tract signs and symptoms NEC | | |
| Pelvic pain | 3 | 0 |
| Sexual function and fertility disorders NEC | | |
| Dyspareunia | 1 | 0 |
| Infertility | 1 | 0 |
| Uterine disorders NEC | | Ŭ |
| Endometriosis | 1 | 0 |
| Vulvovaginal disorders NEC | | Ū |
| Vaginal haemorrhage | 2 | 0 |
| Vulval ulceration | 1 | 0 |
| Vulvovaginal signs and symptoms | | 0 |
| Coital bleeding | 1 | 0 |
| Reproductive & breast disorders SOC TOTAL | 81 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Respiratory disorders | | |
| Breathing abnormalities | | |
| Dysphoea | 6 | 6 0 |
| Grunting | | 1 0 |
| Hyperventilation | 1 | 7 0 |
| Hypopnoea | | 8 C |
| Respiration abnormal | | 2 0 |
| Respiratory arrest | | 4 C |
| Tachypnoea | | 2 0 |
| Bronchospasm and obstruction | | |
| Asthma | | 9 0 |
| Bronchospasm | | 5 0 |
| Obstructive airways disorder | | 2 0 |
| Wheezing | | 5 0 |
| Coughing and associated symptoms | | |
| Allergic cough | | 1 C |
| Cough | 1 | |
| Productive cough | | 2 0 |
| Laryngeal and adjacent sites disorders NEC neoplasms) | | |
| Vocal cord disorder | | 1 0 |
| Laryngeal spasm, oedema and obstruction | | |
| Laryngospasm | | 1 0 |
| Lower respiratory tract signs and symptoms | | |
| Pleuritic pain | | 1 0 |
| Nasal congestion and inflammations | | |
| Nasal congestion | | 3 0 |
| Nasal disorders NEC | | |
| Epistaxis | 1 | 1 0 |
| Pharyngeal disorders (excl infections and ne | | |
| Pharyngeal erythema | | 1 0 |
| Pharyngeal paraesthesia | | 1 0 |
| Pharyngeal swelling | | 2 0 |
| Pneumothorax and pleural effusions NEC | | |
| Pneumothorax | | 1 0 |
| Pulmonary oedemas | | |
| Pulmonary oedema | | 1 0 |
| Respiratory tract disorders NEC | | |
| Allergic respiratory disease | | 1 C |
| Respiratory disorder | | 1 1 |
| Respiratory tract inflammation | | 1 0 |
| Upper respiratory tract signs and symptoms | | |
| Choking sensation | | 1 0 |
| Dry throat | | 1 0 |
| Dysphonia | | 2 0 |
| Oropharyngeal discomfort | | 1 0 |
| Oropharyngeal pain | 3 | |
| Rhinorrhoea | 5 | 2 0 |
| Sinus pain | | 2 0 |
| Throat irritation | 1 | |
| Throat tightness | | 8 0 |
| Respiratory disorders SOC TOTAL | 22 | |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-----------------|----------|
| Skin disorders | | |
| Acnes | | |
| Acne | 4 | . C |
| Acne cystic | 1 | C |
| Alopecias | | |
| Alopecia | 13 | c C |
| Alopecia areata | 2 | |
| Diffuse alopecia | 1 | |
| Madarosis | 1 | |
| Angioedemas | | |
| Angioedema | 5 | |
| Apocrine and eccrine gland disorders | | |
| Cold sweat | 43 | |
| Hyperhidrosis | 32 | |
| Miliaria | 1 | |
| Night sweats | 1 | |
| Bullous conditions | | |
| Blister | 2 | c c |
| Erythema multiforme | | |
| Dermal and epidermal conditions NEC | | |
| Dry skin | 6 | C C |
| Pain of skin | 2 | |
| Papule | | - |
| Scab | 1 | |
| Skin burning sensation | 1 | |
| Skin discolouration | 27 | |
| Skin reaction | 3 | |
| Skin tightness | | |
| Skin warm | 14 | - |
| Dermatitis and eczema | | |
| Dermatitis allergic | 14 | . 0 |
| Dermatitis contact | 1 | |
| Eczema | 6 | |
| Eczema nummular | 1 | |
| Skin irritation | 4 | |
| Dermatitis ascribed to specific agent | 4 | |
| Drug eruption | 1 | C |
| Erythemas | | |
| Erythema | 52 | e c |
| Palmar erythema | | |
| Exfoliative conditions | | |
| Skin exfoliation | | s c |
| | 3 | |
| <i>Hyperpigmentation disorders</i> Melanoderma | 1 | C |
| | d infoctations) | |
| Nail and nail bed conditions (excl infections an Nail discolouration | | |
| | | C |
| Panniculitides | | |
| Erythema nodosum | 3 | |
| Papulosquamous conditions | | |
| Pityriasis rosea | 2 | 2 C |
| Photosensitivity and photodermatosis condition | | |
| Photosensitivity reaction | 6 | |
| Pigmentation changes NEC | | - |
| Pigmentation disorder | I1 | <u> </u> |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|--------------------------------------|-------|-------|
| Skin disorders Skin disorders cont'd | | |
| Pruritus NEC | | |
| Pruritus | 57 | 7 0 |
| Psoriatic conditions | | |
| Psoriasis | 1 | 0 |
| Purpura and related conditions | | |
| Henoch-Schonlein purpura | | 5 0 |
| Petechiae | 4 | - |
| Purpura | 3 | 3 0 |
| Rashes, eruptions and exanthems NEC | | |
| Rash | 105 | |
| Rash erythematous | 21 | |
| Rash macular | 19 | |
| Rash maculo-papular | 2 | |
| Rash papular | | |
| Rash pruritic | 15 | 5 0 |
| Rash vesicular | 1 | 0 |
| Skin and subcutaneous conditions NEC | | |
| Skin mass | 1 | 0 |
| Umbilical discharge | 1 | 0 |
| Skin hyperplasias and hypertrophies | | |
| Skin hypertrophy | 1 | 0 |
| Skin hypoplasias and atrophies | | |
| Skin striae | 2 | 2 0 |
| Skin preneoplastic conditions NEC | | |
| Precancerous skin lesion | 1 | 0 |
| Skin vasculitides | | |
| Vasculitic rash | 1 | 0 |
| Skin vasomotor conditions | | |
| Livedo reticularis | 19 | 0 0 |
| Urticarias | | |
| Urticaria | 86 | |
| Skin disorders SOC TOTAL | 615 | 5 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Social circumstances | | |
| Disability issues | | |
| Bedridden | 2 | 0 |
| Loss of personal independence in daily activities | 6 | 0 |
| Physical disability | 1 | 0 |
| Educational issues | | |
| Educational problem | 1 | 0 |
| Social circumstances SOC TOTAL | 10 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Reaction Name | Total | Fatal |
|---|-------|-------|
| Surgical & medical procedures | | |
| Hernia repairs | | |
| Inguinal hernia repair | 1 | 0 |
| Obstetric therapeutic procedures | | |
| Vacuum extractor delivery | 1 | 0 |
| Ovarian therapeutic procedures | | |
| Oophorectomy | 1 | 0 |
| Psychiatric therapies | | |
| Antidepressant therapy | 1 | 0 |
| Surgical & medical procedures SOC TOTAL | 4 | 0 |

Name: GARDASIL - Product Analysis Print

Report Run Date: 02-Aug-2021 Earliest Reaction Date: 05-May-2006

| Vascular disordersImage: style styl | Reaction Date: 05-May-2006 MedDRA Version: MedDRA 24.0 | Total | Fatal |
|---|--|-------|--------------|
| Blood pressure disorders NECIBlood pressure fluctuation1Circulatory collapse and shock1Circulatory collapse1Shock2Haemorrhages NEC2Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Vascular pain1Vascular pain1Vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorders NEC31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypotensive disorders NEC1Hypertension1Orthostatic hypetension1Orthostatic hypetension1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1 <th></th> <th>Total</th> <th><u>ralai</u></th> | | Total | <u>ralai</u> |
| Blood pressure fluctuation1Circulatory collapse and shock1Circulatory collapse1Shock2Haemorrhages NEC1Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder31Por peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypotension1Orthostatic hypetnesion1Vascular hypotension1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | | |
| Circulatory collapse and shock1Circulatory collapse1Shock2Haemorrhage NEC2Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vascular pain1Vascular pain1Vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorders NEC31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypettension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | c |
| Circulatory collapse1Shock2Haemorrhage NEC1Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vasodilatation1Peripheral vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorders NEC31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypotension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | | |
| Shock2Haemorrhages NEC1Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vasodilatation1Peripheral vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorders NEC31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | c |
| Haemorrhages NEC1Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vascular pain1Vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitis13Orthostatic hypotension1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 2 | |
| Venous haemorrhage1Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vascular pain1Peripheral vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vasconstriction, necrosis and vascular insufficiency1Peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vasculitides NEC1Hypotension1Vasculitis1Vasc | | | |
| Non-site specific embolism and thrombosis1Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vasodilatation1Peripheral vascular disorders NEC10Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vasconstriction, necrosis and vascular insufficiency31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC126Vascular hypertensive disorders NEC126Vascular hypertensive disorders NEC1Hypettension1Orthostatic hypertension1Vascular hypotensive disorders1Hypotension1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | C |
| Thrombosis1Non-site specific vascular disorders NEC1Vascular pain1Vasodilatation1Peripheral vascular disorders NEC1Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder1Peripheral vasconstriction, necrosis and vascular insufficiency31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotension1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | | |
| Vascular pain1Vasodilatation1Peripheral vascular disorders NEC10Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder31Poor peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotension13Orthostatic hypotension13Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | c c |
| Vascular pain1Vasodilatation1Peripheral vascular disorders NEC10Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascular disorder31Poor peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotension13Orthostatic hypotension13Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Non-site specific vascular disorders NEC | | |
| Peripheral vascular disorders NEC10Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vasconstriction, necrosis and vascular insufficiency31Poor peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotension1Vasculitides NEC1Vasculitis1Vasculitis1Vasculitis1Vascular hypotension1Uthostatic hypotension1Vasculitis1Vascular hypotension1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | C |
| Cyanosis10Flushing27Hot flush4Peripheral vascular disorder1Peripheral vascoonstriction, necrosis and vascular insufficiency31Poor peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitides NEC1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | C C |
| Flushing27Hot flush4Peripheral vascular disorder1Peripheral vasconstriction, necrosis and vascular insufficiency31Peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Peripheral vascular disorders NEC | | |
| Flushing27Hot flush4Peripheral vascular disorder1Peripheral vasconstriction, necrosis and vascular insufficiency31Peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitides NEC1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | - | 10 | C C |
| Peripheral vascular disorder1Peripheral vasoconstriction, necrosis and vascular insufficiency1Peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitides NEC1Vasculitides NEC1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 27 | C |
| Peripheral vasoconstriction, necrosis and vascular insufficiency31Peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitides NEC1Vasculitides NEC1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Hot flush | 4 | C |
| Peripheral coldness31Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vascular hypotensive disorders1Vascular hypotensive disorders1Vasculitides NEC1Vasculitis1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Peripheral vascular disorder | 1 | 0 |
| Poor peripheral circulation3Raynaud's phenomenon1Site specific vascular disorders NEC1Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Vascular hypotensive disorders1Vascular hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Peripheral vasoconstriction, necrosis and vascular insufficiency | | |
| Raynaud's phenomenon1Site specific vascular disorders NEC126Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitides NEC1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Peripheral coldness | 31 | C |
| Site specific vascular disorders NEC126Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitis1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Poor peripheral circulation | 3 | C |
| Pallor126Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Hypotension13Orthostatic hypotension11Vasculitides NEC1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | | 1 | C |
| Vascular hypertensive disorders NEC1Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Site specific vascular disorders NEC | | |
| Hypertension1Orthostatic hypertension1Vascular hypotensive disorders1Hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Pallor | 126 | C |
| Orthostatic hypertension1Vascular hypotensive disorders1Hypotension13Orthostatic hypotension1Vasculitides NEC1Vasculitis1Vascular disorders SOC TOTAL228TOTAL REACTIONS FOR DRUG7562 | Vascular hypertensive disorders NEC | | |
| Vascular hypotensive disorders 13 Hypotension 13 Orthostatic hypotension 1 Vasculitides NEC 1 Vasculitis 1 Vascular disorders SOC TOTAL 228 TOTAL REACTIONS FOR DRUG 7562 | | 1 | C |
| Hypotension 13 Orthostatic hypotension 1 Vasculitides NEC 1 Vasculitis 1 Vascular disorders SOC TOTAL 228 TOTAL REACTIONS FOR DRUG 7562 | | 1 | C |
| Orthostatic hypotension 1 Vasculitides NEC 1 Vasculitis 1 Vascular disorders SOC TOTAL 228 TOTAL REACTIONS FOR DRUG 7562 | | _ | |
| Vasculitides NEC 1 Vasculitis 1 Vascular disorders SOC TOTAL 228 TOTAL REACTIONS FOR DRUG 7562 | | 13 | |
| Vasculitis 1 Vascular disorders SOC TOTAL 228 TOTAL REACTIONS FOR DRUG 7562 | | 1 | C |
| Vascular disorders SOC TOTAL 228 TOTAL REACTIONS FOR DRUG 7562 | | | |
| TOTAL REACTIONS FOR DRUG 7562 | | 1 | C |
| | | | |
| | TOTAL REACTIONS FOR DRUG | 7562 | 5 |
| | TOTAL REPORTS | 2449 | |
| TOTAL FATAL OUTCOME REPORTS | | 2443 | 5 |